The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly ...
The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback